tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ACRV Stock Latest News

Optimistic Buy Rating for Acrivon Therapeutics, Inc. Driven by Promising ACR-368 Trial Developments
RatingsOptimistic Buy Rating for Acrivon Therapeutics, Inc. Driven by Promising ACR-368 Trial Developments
5d ago
ACRV
3 Best Stocks to Buy Now, 11/14/2025, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy Now, 11/14/2025, According to Top Analysts
16d ago
ACRV
DASH
Positive Outlook and Buy Rating for Acrivon Therapeutics, Inc. Based on Promising Clinical Data and Strategic Advancements
PremiumRatings
Positive Outlook and Buy Rating for Acrivon Therapeutics, Inc. Based on Promising Clinical Data and Strategic Advancements
16d ago
ACRV
Acrivon Therapeutics Reports Q3 2025 Financial Results
PremiumCompany Announcements
Acrivon Therapeutics Reports Q3 2025 Financial Results
17d ago
ACRV
Acrivon Therapeutics reports Q3 EPS (47c), consensus (58c)
PremiumThe Fly
Acrivon Therapeutics reports Q3 EPS (47c), consensus (58c)
17d ago
ACRV
Analysts Predict Up to 550% Rally for These 2 ‘Strong Buy’ Penny Stocks
PremiumMarket NewsAnalysts Predict Up to 550% Rally for These 2 ‘Strong Buy’ Penny Stocks
29d ago
ACRV
VTGN
Acrivon Therapeutics’ Phase 1 Study of ACR-2316: Key Updates and Market Implications
Premium
Company Announcements
Acrivon Therapeutics’ Phase 1 Study of ACR-2316: Key Updates and Market Implications
1M ago
ACRV
Acrivon Therapeutics Advances Phase 2 Study for Endometrial Cancer Treatment
Premium
Company Announcements
Acrivon Therapeutics Advances Phase 2 Study for Endometrial Cancer Treatment
1M ago
ACRV
Acrivon Therapeutics Highlights Synergy in Updated Presentation
PremiumCompany Announcements
Acrivon Therapeutics Highlights Synergy in Updated Presentation
3M ago
8K
ACRV
Acrivon Therapeutics, Inc.: Promising Clinical Developments and Strong Financial Position Justify Buy Rating
PremiumRatings
Acrivon Therapeutics, Inc.: Promising Clinical Developments and Strong Financial Position Justify Buy Rating
4M ago
ACRV
Acrivon Therapeutics price target lowered to $8 from $9 at Oppenheimer
PremiumThe Fly
Acrivon Therapeutics price target lowered to $8 from $9 at Oppenheimer
4M ago
ACRV
Acrivon Therapeutics, Inc. Receives Buy Rating Due to Promising Clinical Data and Strategic Trial Expansion
PremiumRatings
Acrivon Therapeutics, Inc. Receives Buy Rating Due to Promising Clinical Data and Strategic Trial Expansion
4M ago
ACRV
Acrivon Therapeutics Reports Q2 2025 Financial Results
PremiumCompany AnnouncementsAcrivon Therapeutics Reports Q2 2025 Financial Results
4M ago
ACRV
Acrivon Therapeutics reports Q2 EPS (55c), consensus (58c)
Premium
The Fly
Acrivon Therapeutics reports Q2 EPS (55c), consensus (58c)
4M ago
ACRV
Acrivon Therapeutics Holds Annual Stockholders Meeting
Premium
Company Announcements
Acrivon Therapeutics Holds Annual Stockholders Meeting
6M ago
8K
ACRV
Acrivon Therapeutics: Promising Clinical Developments and Strategic Focus Support Buy Rating
PremiumRatings
Acrivon Therapeutics: Promising Clinical Developments and Strategic Focus Support Buy Rating
6M ago
ACRV
Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch
PremiumThe Fly
Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch
7M ago
ACRV
Acrivon Therapeutics, Inc.: Promising Clinical Data and Strategic Advancements Justify Buy Rating
PremiumRatings
Acrivon Therapeutics, Inc.: Promising Clinical Data and Strategic Advancements Justify Buy Rating
7M ago
ACRV
Acrivon Therapeutics Reports Q1 2025 Progress and Financials
PremiumCompany Announcements
Acrivon Therapeutics Reports Q1 2025 Progress and Financials
7M ago
ACRV
Acrivon Therapeutics price target lowered to $9 from $10 at Oppenheimer
PremiumThe FlyAcrivon Therapeutics price target lowered to $9 from $10 at Oppenheimer
7M ago
ACRV
Optimistic Outlook for Acrivon Therapeutics: Promising ACR-368 Results and Strategic Focus on Endometrial Cancer
Premium
Ratings
Optimistic Outlook for Acrivon Therapeutics: Promising ACR-368 Results and Strategic Focus on Endometrial Cancer
7M ago
ACRV
Acrivon Therapeutics reports Q1 EPS (51c), consensus (65c)
Premium
The Fly
Acrivon Therapeutics reports Q1 EPS (51c), consensus (65c)
7M ago
ACRV

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >